Risks of harms using antifibrinolytics in cardiac surgery: Systematic review and network meta-analysis of randomised and observational studies

BMJ (Online)

Volumn 345, Issue 7877, 2012, Pages

  Hutton, Brian ^a   Joseph, Lawrence ^b   Fergusson, Dean ^a   Mazer, C David ^c   Shapiro, Stan ^b   Tinmouth, Alan ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DEATH; HEART INFARCTION; HEART SURGERY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; POSTOPERATIVE COMPLICATION; REVIEW; RISK;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY; RISK; STROKE; TRANEXAMIC ACID;

EID: 84867281693     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e5798     Document Type: Article

References (36)

1. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31. (Pubitemid 351749156)
2. McMullan V, Alston RP. The effect of the suspension of the license for aprotinin on the care of patients undergoing cardiac surgery: a survey of cardiac anesthesiologists' and surgeons' opinions in the United Kingdom. Cardiothorac Vasc Anesth 2010;24:418-21.
3. Sniecinski RM, Chen EP, Makadia SS, Kikura M, Bolliger D, Tanaka KA. Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth 2010;24:959-63.
4. Strouch Z, Drum M, Chaney M. Aprotinin use during cardiac surgery: recent alterations and effects on blood product utilization. J Clin Anesth 2009;21:502-7.
5. Bennett-Guerrero E, Song HK, Zhao Y, Ferguson TB Jr, Gammie JS, Peterson ED, et al. Temporal changes in the use of blood products for coronary artery bypass graft surgery in North America: an analysis of the Society of Thoracic Surgeons Adult Cardiac Database. J Cardiothorac and Vasc Anesth 2010;24:814-6.
6. European Medicines Agency. European Medicines Agency recommends lifting of suspension of aprotinin. 2012. www.ema.europa.eu/docs/en-GB/document-library/ Press- release/2012/02/WC500122914.pdf.
7. Bradburn M, Deeks J, Berlin J, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-anaytical methods with rare events. Stat Med 2007;26:53-77. (Pubitemid 46099417)
8. Sweeting MJ, Sutton A, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75. (Pubitemid 38594143)
9. Sutton A, Cooper N, Lambert P, Jones D, Abrams K, Sweeting M. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res 2002;2:367-79.
10. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011;16(3):CD001886.
11. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2012. www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
12. Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24. (Pubitemid 39334902)
13. Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Last updated Aug 2011. www.nicedsu.org.uk. 2011.
14. Riley R, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342.d549.
15. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment. Last updated April 2012. www.nicedsu.org.uk. 2011.
16. Salanti G, Ades AE, Ioannidis J. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
17. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian data analysis, 2nd edn. Chapman and Hall, 2003.
18. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44.
19. Mangano DT, Tudor JC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65. (Pubitemid 43145060)
20. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006;46:327-38. (Pubitemid 43334084)
21. Karkouti K, Wijeysundera D, Yau T, McCluskey S, Tait G, Beattie W. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010;110:21-9.
22. Olenchock SA Jr, Lee PH, Yehoshua T, Murphy SA, Symes J, Tolis G Jr. Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients. Ann Thorac Surg 2008;86:560-6; discussion 566-7.
23. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminatham M, Milano C, et al. The effect of aprotinin on outcome after coronary artery bypass grafting. N Engl J Med 2008;358:784-93. (Pubitemid 351284456)
24. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83. (Pubitemid 351284455)
25. Stamou S, Reames M, Skipper E, Stiegel RM, Nussbaum M, Geller R, et al. Aprotinin in cardiac surgery patients: is the risk worth the benefit? Eur J Cardiothorac Surg 2009;36:869-75.
26. Ngaage DL, Cale AR, Cowen ME, Griffin S, Guvendik L. Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study. Ann Thorac Surg 2008;86:1195-202.
27. Jakobsen C, Sondergaard F, Hjortdal V, Johnsen S. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study. Eur J Cardiothorac Surg 2009;36:863-8.
28. Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, et al. Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery. Ann Thorac Surg 2010;89:1489-95.
29. Gillespie EL, Gryskiewicz K, White M, Kluger J, Humphrey C, Horotwitz S, et al. Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter. Am J Health Syst Pharm 2005;62:1370-4. (Pubitemid 40979688)
30. Rahman Z, Hoque R, Ali A, Rahman M, Rahman MS. Blood conservation strategies for reducing peri-operative blood loss in open heart surgery. Mymensingh Med 2011;20:45-53.
31. Muedra V, Delas F, Villalonga V, Gomez M, Sanchez F, Llopis JE. Transfusion requirements, morbidity and mortality in cardiac surgery and the use of antifibrinolytic agents: a comparison of aprotinin and tranexamic acid. Rev Esp Anestesiol Reanim 2011;58:140-6.
32. Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Vasc Anesth 2004;8:267-81. (Pubitemid 39603175)
33. Brown J, Birkmeyer N, O'Connor G. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801-13. (Pubitemid 46876483)
34. Levi M, Cromheecke M, de Jonge E, Prins M, de Mol BJ, Briet E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-7.
35. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-67. (Pubitemid 28130521)
36. Carless P, Moxey AJ, Stokes BJ, Henry D. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-head trials. BMC Cardiovasc Disord 2005;5:19.